Portal Instruments, a leader in innovative drug delivery solutions, will showcase its new device, PRIME Nexus, at the Pre-Filled Syringes and Injectable Drug Devices conference in Boston, April 28-30.
BOSTON, MA – April 8, 2025 – Portal Instruments, a leader in innovative drug delivery solutions, will showcase its new device, PRIME Nexus, at the Pre-Filled Syringes and Injectable Drug Devices conference in Boston, April 28-30.
PRIME Nexus is a reusable electro-mechanical autoinjector, leveraging Portal’s PRIME needle-free platform. Compatible with 1.0 mL and 2.25 mL pre-filled syringes, Nexus offers a sustainable solution for a wide range of injectable medications and is currently available for feasibility studies.
Attendees are invited to meet with CCO Steven Kaufman for personalized demonstrations and to discuss the device's capabilities. “We’re thrilled to present PRIME Nexus alongside Gerresheimer at the PFS conference,” stated Kaufman. “The surge in injectable therapies, exemplified by GLP-1 drugs, necessitates a shift towards reusable solutions to mitigate the significant waste generated by single-use devices. PRIME Nexus represents a forward-thinking approach to injector technology.”
For companies traveling to Boston, the Portal team extends an invitation to visit their Cambridge office for a closer look at their technology.
February 11, 2020 - Gerresheimer recently published an article describing Portal Instrument’s innovative primary drug container which is used in Portal’s needle-free drug delivery platform. Read the full pdf article here.
June 2021 - Needles are a 150-year-old technology. The world around us is rapidly evolving but drug delivery has not made the same technological strides that other medical devices have. Portal Instruments is looking to change that with a highly innovative needle-free drug delivery injector.
Today Portal Instruments announced a joint publication with Regeneron on the PRIME needle-free injection platform. The findings provided crucial data on Portal's platform, demonstrating the ability to deliver high-viscosity biologics with volume flexibility and tailored injection depths.
Please fill out the details below and we will get back to you shortly.